Диссертация (1139777), страница 19
Текст из файла (страница 19)
Oyen R.H., Van Poppel H.P., Ameye F.E. et al. Lymph node staging of localizedprostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy:prospective study of 285 patients. // Radiology, 1994; 190: 315–322.70. Hricak H., Schoder H., Pucar D. et al. Advances in imaging in the postoperativepatient with a rising prostatespecific antigen level. // Semin Oncol, 2003; 30(5):616–634.71. Taoka T., Mayr N.A., Lee H.J. et al.
Factors influencing visualization of vertebralmetastases on MR imaging versus bone scintigraphy. // AJR Am J Roentgenol,2001; 176(6): 1525–1530.72. Turner J.W., Hawes D.R., Williams R.D. Magnetic resonance imaging fordetection of prostate cancer metastatic to bone. // J Urol, 1993; 149 (6): 1482–1484.73. Ахвердиева Г.И. Топическая МРТ-диагностика локализованного ракапредстательной железы и его рецидивов после радикальной простатэктомии:дис. … автореферат канд. мед. наук: 14.01.13 / Ахвердиева Гюля ИльгарКызы. – М., 2014.
– 24с.74. Sella T., Schwartz L.H., Swindle P.W. et al. Suspected local recurrence afterradical prostatectomy: endorectal coil MR imaging. // Radiology, 2004; 231(2):379–385.75. Hövels A.M., Heesakkers R.A., Andag E.M. et al. The diagnostic accuracy of CTand MRI in the staging of pelvic lymph nodes in patients with prostate cancer: ameta-analysis. // Clin Radiol, 2008; 63: 387–395.76.
Silverman J.M., Krebs T.L. MR imaging evaluation with a transrectal surface coilof local recurrence of prostatic cancer in men who have undergone radical119prostatectomy. // AJR Am J Roentgenol, 1997; 168(2): 379–385.77. Глыбочко П.В. Локальный рецидив рака предстательной железы упациентов после радикальной простатэктомии. Современные методыдиагностики и лечения (эндоректальная магнитно-резонансная томография сконтрастным усилением, гистосканирование, ВИФУ) // П.В. Глыбочко, Ю.Г.Аляев, А.В.
Амосов/ Клиническая неврология. – 2014. – №4. – С. 43–50.78.Casciani E., Polettini E., Carmenini E. et al. Endorectal and dynamic contrastenhanced MRI for detection of local recurrence after radical prostatectomy. // AJRAm J Roentgenol, 2008; 190(5): 1187–1192.79. Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imagingat 1.5 Tesla to assess local recurrence following radical prostatectomy using T2weighted and contrast-enhanced imaging.
// Eur Radiol, 2009; 19(3): 761–769.80. Sciarra A, Panebianco V, Salciccia S, et al. Role of dynamic contrast-enhancedmagnetic resonance (MR) imaging and proton MR spectroscopic imaging in thedetection of local recurrence after radical prostatectomy for prostate cancer. // EurUrol, 2008; 54(3): 589–600.81.
Pucar D., Sella T., Schoder H. The role of imaging in the detection of prostatecancer local recurrence after radiation therapy and surgery. // Curr Opin Urol,2008; 18(1): 87–97.82. Москаленко Е.А. Современный подход к диагностике рака предстательнойжелезысиспользованиеммагнитно-резонанснойспектроскопии(клиническое исследование) / Е.А. Москаленко, С.Б Петров, Ю.В. Толкач,А.В.
Мищенко // Онкоурология. – 2011. – №1. – С. 25 – 30.83. Kurhanewicz J., Vigneron D.B., Hricak H., et al. Prostate cancer: metabolicresponse to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. //Radiology, 1996; 200(2): 489–496.84. Coakley F.V., Teh H.S., Qayyum A. et al. Endorectal MR imaging and MRspectroscopic imaging for locally recurrent prostate cancer after external beamradiation therapy: preliminary experience. // Radiology, 2004; 233(2): 441–448.85.
Westphalen A.C., Coakley F.V., Roach M. et al. Locally recurrent prostate cancer120after external beam radiation therapy: diagnostic performance of 1.5-T endorectalMR imaging and MR spectroscopic imaging for detection. // Radiology, 2010;256(2): 485–492.86.
Haider M.A., Chung P., Sweet J. et al. Dynamic contrast-enhanced magneticresonance imaging for localization of recurrent prostate cancer after external beamradiotherapy. // Int J Radiat Oncol Biol Phys, 2008, 70(2): 425–430.87. Rouviere O., Valette O., Grivolat S. et al. Recurrent prostate cancer after externalbeam radiotherapy: value of contrast-enhanced dynamic MRI in localizingintraprostatic tumor--correlation with biopsy findings.
// Urology, 2004, 63(5):922–927.88. Kim C.K., Park B.K., Park W., Kim S.S. Prostate MR imaging at 3T using aphased-arrayed coil in predicting locally recurrent prostate cancer after radiationtherapy: preliminary experience. // Tamsel, S. 2010, 35(2): 246–252.89. Bammer R. Basic principles of diffusion-weighted imaging. // Eur Radiol, 2003;45: 169–184.90. КарельскаяН.А.Диффузионно-взвешеннаямагнитно-резонанснаятомография всего тела / Н.А.
Карельская, Кармазановский Г.Г. // Хирургия.— 2010. — №8. — С. 57–60.91. Kim C.K., Park B.K., Kim B. Diffusion-weighted MRI at 3 T for the evaluation ofprostate cancer. //AJR Am J Roentgenol, 2010; 194(6): 1461–1469.92. Nakanishi K., Kobayashi M., Nakaguchi K., et al. Whole-body MRI for detectingmetastatic bone tumor: diagnostic value of diffusion-weighted images.
// MagnReson Med Sci, 2007; 6(3): 147–155.93. Kim C.K., Park B.K., Lee H.M. Prediction of locally recurrent prostate cancerafter radiation therapy: incremental value of 3T diffusion-weighted MRI. // Kim,C. K, 2009; 29(2): 391–397.94. Harisinghani M.G., Barentsz J., Hahn P.F. et al. Noninvasive detection ofclinically occult lymph-node metastases in prostate cancer.
// N Engl J Med, 2003;348(25): 2491–2499.95. Gillies R.J., Robey I., Gatenby R.A. Causes and consequences of increased121glucose metabolism of cancers. // J Nucl Med, 2008; 49, Suppl. 6: 24–42.96. Jadvar H., Pinski J., Quinn D. et al. PET/CT with FDG in metastatic prostatecancer: castratesensitivevs. castrate-resistant disease. // J Nucl Med, 2009; 50:120.97. Jadvar H., Desai B., Ji L. et al. Comparison of Imaging- and PSA-BasedTreatment Response Criteria in Metastatic Prostate Cancer: A PreliminaryAnalysis. // RSNA 97th Scientific Assembly & Ann Meeting, Chicago, IL, 2011.98.
Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancerby positron emission tomography with 18fluorine-labeled deoxyglucose. // J Urol,1996; 155(3): 994–998.99. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or11C-choline. // J Nucl Med, 2011; 52(1): 81–89.100.Hofer C., Laubenbacher C., Block T. et al. Fluorine-18-fluorodeoxyglucosepositron emission tomography is useless for the detection of local recurrence afterradical prostatectomy. // Eur Urol, 1999; 36: 31–35.101.Liu I.J., Zafar M.B., Lai Y.H.
et al. Fluorodeoxyglucose positron emissiontomography studies in diagnosis and staging of clinically organ-confined prostatecancer. // Urology, 2001; 57: 108–111.102.Fanti S., Nanni C., Ambrosini V. et al. PET in genitourinary tract cancers.// Eur J Nucl Med Mol Imaging, 2007; 51: 260–271.103.Chang C.H., Wu H.C., Tsai J.J.
et al. Detecting metastatic pelvic lymphnodes by 18F-2-deoxyglucose positron emission tomography in patients withprostate-specific antigen relapse after treatment for localized prostate cancer. //Urol Int, 2003; 70: 311–315.104.Schoder H., Herrmann K., Gonen M. et al. 2-[18F] fluoro-2-deoxyglucosepositron emission tomography for detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy.
// Clin Cancer Res, 2005; 11:4761–4769.105.Effert P., Beniers A.J., Tamimi Y. et al. Expression of glucose transporter 1(GLUT-1) in cell lines and clinical specimen from human prostate122adenocarcinoma. // Anticancer Res, 2004; 24: 3057.106.Oyama N., Akino H., Suzuki Y. et al. FDG PET for evaluating the change ofglucose metabolism in prostate cancer after androgen ablation.
// Nucl MedCommun, 2001; 22: 963–969.107.Jadvar H., Desai B., Quinn D. Treatment Response Assessment ofMetastatic Prostate Cancer with FDG PET/CT. // J Nucl Med, 2011; 52, Suppl. 1:431.108.Oyama N., Akino H., Suzuki Y. et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients withprostate cancer. // Mol Imaging Biol, 2002; 4: 99–104.109.Meirelles G.S., Schoder H., Ravizzini G.C. et al. Prognostic value ofbaseline [18F]fluorodeoxyglucose positron emission tomography and 99mTcMDP bone scan in progressing metastatic prostate cancer. // Clin Cancer Res,2010; 16: 6093–6099.110.Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostatecancer. // Prostate Cancer and Prostatic Diseases, 2006; 9: 230–234.111.Soloviev D., Fini A., Chierichetti F.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
